MedTrace Logo

A Phase 3 Clinical Study Patients With Androgenetic Alopecia (AGA)

NCT05135468 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 270

Last updated 2023-08-01

No results posted yet for this study

Summary

A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Clinical Study ,the mean change from baseline in vertex target area hair count (TAHC) after treatment for 24 weeks.

Conditions

  • AGA

Interventions

DRUG

CU-40102 Spray

topical application, 1\~4 sprays each time, once daily

Sponsors & Collaborators

  • Cutia Therapeutics（Wuxi）Co.,Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
41 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-06
Primary Completion
2023-03-07
Completion
2023-05-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05135468 on ClinicalTrials.gov